Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
115.96
+6.36 (5.80%)
At close: Aug 14, 2026, 4:00 PM EDT
117.00
+1.04 (0.90%)
After-hours: Aug 14, 2026, 7:34 PM EDT
Dianthus Therapeutics Employees
Dianthus Therapeutics had 92 employees as of December 31, 2025. The number of employees increased by 14 or 17.95% compared to the previous year.
Employees
92
Change (1Y)
14
Growth (1Y)
17.95%
Revenue / Employee
$20,696
Profits / Employee
-$2,089,630
Market Cap
6.49B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 92 | 14 | 17.95% |
| Dec 31, 2024 | 78 | 25 | 47.17% |
| Dec 31, 2023 | 53 | 21 | 65.63% |
| Jun 30, 2023 | 43 | - | - |
| Mar 31, 2023 | 32 | - | - |
| Dec 31, 2022 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| PTC Therapeutics | 991 |
| Mirum Pharmaceuticals | 433 |
| TG Therapeutics | 399 |
| Xenon Pharmaceuticals | 370 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
| CG Oncology | 142 |
DNTH News
- 9 days ago - Dianthus price target raised to $128 from $110 at Truist - TheFly
- 10 days ago - Dianthus price target raised to $158 from $130 at H.C. Wainwright - TheFly
- 10 days ago - Dianthus price target raised to $122 from $105 at Wedbush - TheFly
- 11 days ago - Dianthus reports Q2 EPS (90c), consensus (91c) - TheFly
- 11 days ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results - GlobeNewsWire
- 11 days ago - Dianthus Therapeutics Earnings release: Q2 2026 - Filings
- 11 days ago - Dianthus Therapeutics Quarterly report: Q2 2026 - Filings
- 11 days ago - Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases - GlobeNewsWire